Skip to Content
Merck
CN

SML1200

RO8191

≥98% (HPLC)

Synonym(s):

8-(1,3,4-Oxadiazol-2-yl)-2,4-bis(trifluoromethyl)-imidazo[1,2-a][1,8]naphthyridine, RO4948191

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C14H5F6N5O
CAS Number:
691868-88-9
Molecular Weight:
373.21
UNSPSC Code:
51111800
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

GRHYZVJEXKTJOS-UHFFFAOYSA-N

SMILES string

FC(F)(F)c1nc2[n]3c(nc(c3)c4nnc[o]4)ccc2c(c1)C(F)(F)F

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 0.5 mg/mL, clear (warmed)

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

RO8191 is a potent and specific type I interferon receptor agonist that directly binds to IFN-α receptor 2 (IFNAR2).
RO8191 is an imidazonaphthyridine compound, which activates interferon (IFN) signals, IFN-stimulated genes (ISGs) expression and Janus kinase (JAK)/signal transducers and activators of transcription (STAT) phosphorylation.
RO8191 is an orally available, potent and specific type I interferon receptor agonist that directly binds to IFN-α receptor 2 (IFNAR2). RO8191 suppresses HCV replication without inducing host cell toxicity.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000401922
0000401922
0000130246
0000130247
0000071073

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hideyuki Konishi et al.
Scientific reports, 2, 259-259 (2012-02-23)
Most acute hepatitis C virus (HCV) infections become chronic and some progress to liver cirrhosis or hepatocellular carcinoma. Standard therapy involves an interferon (IFN)-α-based regimen, and efficacy of therapy has been significantly improved by the development of protease inhibitors. However

Articles

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service